ALKS (Alkermes) Cyclically Adjusted Revenue per Share: $8.68 (As of Mar. 2026)


ALKS Alkermes PLC ALKS
64 GF Score
Price $51.95
GF Value $31.67
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Alkermes Cyclically Adjusted Revenue per Share?

Alkermes ALKS -3.39% 64 Cyclically Adjusted Revenue per Share is $8.68 as of Mar. 2026. GuruFocus rates ALKS with a GF Score™ of 64/100 and a GF Value™ of $31.67 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Alkermes's adjusted revenue per share for the three months ended in Mar. 2026 was $2.364. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $8.68 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Alkermes's average Cyclically Adjusted Revenue Growth Rate was 8.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Alkermes was 19.40% per year. The lowest was 4.20% per year. And the median was 11.50% per year.

As of today (2026-07-10), Alkermes's current stock price is $51.95. Alkermes's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $8.68. Alkermes's Cyclically Adjusted PS Ratio of today is 5.99.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Alkermes was 16.57. The lowest was 2.54. And the median was 4.01.


Alkermes  (NAS:ALKS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Alkermes's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=51.95/8.68
=5.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Alkermes was 16.57. The lowest was 2.54. And the median was 4.01.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Alkermes Cyclically Adjusted Revenue per Share Related Terms


Alkermes Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Alkermes's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkermes Cyclically Adjusted Revenue per Share Chart

Alkermes Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.86 6.57 7.35 7.87 8.44

Alkermes Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.98 8.16 8.28 8.44 8.68

ALKS vs HIMS, LNTH, LQDA: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkermes Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Alkermes's Cyclically Adjusted PS Ratio falls into.


ALKS
64GF Score
Alkermes PLC ALKS
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alkermes Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alkermes's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.364/127.8300*127.8300
=2.364

Current CPI (Mar. 2026) = 127.8300.

Alkermes Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.290 101.072 1.632
201609 1.189 100.274 1.516
201612 1.403 99.676 1.799
201703 1.256 100.374 1.600
201706 1.427 100.673 1.812
201709 1.414 100.474 1.799
201712 1.790 100.075 2.286
201803 1.458 100.573 1.853
201806 1.963 101.072 2.483
201809 1.601 101.371 2.019
201812 2.030 100.773 2.575
201903 1.427 101.670 1.794
201906 1.783 102.168 2.231
201909 1.624 102.268 2.030
201912 2.618 102.068 3.279
202003 1.557 102.367 1.944
202006 1.558 101.769 1.957
202009 1.666 101.072 2.107
202012 1.759 101.072 2.225
202103 1.575 102.367 1.967
202106 1.853 103.364 2.292
202109 1.822 104.859 2.221
202112 1.832 106.653 2.196
202203 1.714 109.245 2.006
202206 1.686 112.779 1.911
202209 1.536 113.504 1.730
202212 1.854 115.436 2.053
202303 1.742 117.609 1.893
202306 3.599 119.662 3.845
202309 2.216 120.749 2.346
202312 2.262 120.749 2.395
202403 2.025 120.990 2.139
202406 2.334 122.318 2.439
202409 2.264 121.594 2.380
202412 2.587 122.439 2.701
202503 1.816 123.405 1.881
202506 2.320 124.492 2.382
202509 2.339 124.810 2.396
202512 2.267 125.770 2.304
202603 2.364 127.830 2.364

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $8.68 mean?
Alkermes (ALKS) has a Cyclically Adjusted Revenue per Share of $8.68 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Alkermes and its competitors.
Is Alkermes' Cyclically Adjusted Revenue per Share too high?
Alkermes' current Cyclically Adjusted Revenue per Share is $8.68. Overall, Alkermes has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alkermes' Cyclically Adjusted Revenue per Share compare to HIMS and LNTH?
Alkermes' Cyclically Adjusted Revenue per Share of $8.68 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Alkermes and its competitors. Alkermes's current Cyclically Adjusted Revenue per Share is $8.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkermes stock overvalued right now?
Based on GuruFocus' analysis, Alkermes (ALKS) is currently considered Significantly Overvalued. The stock's GF Value™ is $31.67, compared to a current price of $51.95 — trading 64% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $8.68. Alkermes' overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Alkermes (ALKS), the current Cyclically Adjusted Revenue per Share is $8.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alkermes (ALKS) Overvalued in 2026?

Based on GuruFocus' analysis, Alkermes stock appears to be overvalued. The current stock price of $51.95 is trading 64% above its estimated GF Value™ of $31.67. GuruFocus considers Alkermes to be Significantly Overvalued.

Key valuation signals for ALKS:

  • Cyclically Adjusted Revenue per Share: $8.68
  • GF Value™: $31.67 vs. price of $51.95 (64% above fair value)
  • GF Score™: 64/100 with 8 warning signs

No single metric tells the full story. See the ALKS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alkermes Business Description

Other Exchanges 8AK:Germany
Address 1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
64GF Score

Get the complete analysis for ALKS

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$51.95
Price
$31.67
GF Value